Neuropathic Pain - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：486頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Neuropathic Pain - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Neuropathic Pain - Pipeline Review, H1 2014’, provides an overview of the Neuropathic Pain’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuropathic Pain and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Neuropathic Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Neuropathic Pain - Pipeline Review, H1 2014’, provides an overview of the Neuropathic Pain’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuropathic Pain and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Neuropathic Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 7
Neuropathic Pain Overview 8
Therapeutics Development 9
Neuropathic Pain - Therapeutics under Development by Companies 11
Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 20
Neuropathic Pain - Pipeline Products Glance 23
Neuropathic Pain - Products under Development by Companies 27
Neuropathic Pain - Products under Investigation by Universities/Institutes 38
Neuropathic Pain - Companies Involved in Therapeutics Development 40
Neuropathic Pain - Therapeutics Assessment 148
Drug Profiles 169
Neuropathic Pain - Recent Pipeline Updates 410
Neuropathic Pain - Dormant Projects 454
Neuropathic Pain - Discontinued Products 456
Neuropathic Pain - Product Development Milestones 457
Appendix 463
List of Tables
Number of Products under Development for Neuropathic Pain, H1 2014 31
Number of Products under Development for Neuropathic Pain - Comparative Analysis, H1 2014 32
Number of Products under Development by Companies, H1 2014 34
Number of Products under Development by Companies, H1 2014 (Contd..1) 35
Number of Products under Development by Companies, H1 2014 (Contd..2) 36
Number of Products under Development by Companies, H1 2014 (Contd..3) 37
Number of Products under Development by Companies, H1 2014 (Contd..4) 38
Number of Products under Development by Companies, H1 2014 (Contd..5) 39
Number of Products under Development by Companies, H1 2014 (Contd..6) 40
Number of Products under Development by Companies, H1 2014 (Contd..7) 41
Number of Products under Investigation by Universities/Institutes, H1 2014 43
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 44
Comparative Analysis by Late Stage Development, H1 2014 45
Comparative Analysis by Clinical Stage Development, H1 2014 46
Comparative Analysis by Early Stage Development, H1 2014 47
Comparative Analysis by Unknown Stage Development, H1 2014 48
Products under Development by Companies, H1 2014 49
Products under Development by Companies, H1 2014 (Contd..1) 50
Products under Development by Companies, H1 2014 (Contd..2) 51
Products under Development by Companies, H1 2014 (Contd..3) 52
Products under Development by Companies, H1 2014 (Contd..4) 53
Products under Development by Companies, H1 2014 (Contd..5) 54
Products under Development by Companies, H1 2014 (Contd..6) 55
Products under Development by Companies, H1 2014 (Contd..7) 56
Products under Development by Companies, H1 2014 (Contd..8) 57
Products under Development by Companies, H1 2014 (Contd..9) 58
Products under Development by Companies, H1 2014 (Contd..10) 59
Products under Investigation by Universities/Institutes, H1 2014 60
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 61
Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H1 2014 62
Neuropathic Pain - Pipeline by Genzyme Corporation, H1 2014 63
Neuropathic Pain - Pipeline by Johnson & Johnson, H1 2014 64
Neuropathic Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2014 65
Neuropathic Pain - Pipeline by Biogen Idec Inc., H1 2014 66
Neuropathic Pain - Pipeline by Shionogi & Co., Ltd., H1 2014 67
Neuropathic Pain - Pipeline by AstraZeneca PLC, H1 2014 68
Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2014 69
Neuropathic Pain - Pipeline by Nektar Therapeutics, H1 2014 70
Neuropathic Pain - Pipeline by MedImmune, LLC, H1 2014 71
Neuropathic Pain - Pipeline by Quark Pharmaceuticals, Inc., H1 2014 72
Neuropathic Pain - Pipeline by Merck & Co., Inc., H1 2014 73
Neuropathic Pain - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 74
Neuropathic Pain - Pipeline by Sangamo BioSciences, Inc., H1 2014 75
Neuropathic Pain - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 76
Neuropathic Pain - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 77
Neuropathic Pain - Pipeline by XenoPort, Inc., H1 2014 78
Neuropathic Pain - Pipeline by BioLineRx, Ltd., H1 2014 79
Neuropathic Pain - Pipeline by Neurocrine Biosciences, Inc., H1 2014 80
Neuropathic Pain - Pipeline by Acorda Therapeutics, Inc., H1 2014 81
Neuropathic Pain - Pipeline by Astellas Pharma Inc., H1 2014 82
Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 83
Neuropathic Pain - Pipeline by Eisai Co., Ltd., H1 2014 84
Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2014 85
Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2014 86
Neuropathic Pain - Pipeline by LEO Pharma A/S, H1 2014 87
Neuropathic Pain - Pipeline by Pfizer Inc., H1 2014 88
Neuropathic Pain - Pipeline by Sigma-Tau S.p.A., H1 2014 89
Neuropathic Pain - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 90
Neuropathic Pain - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 91
Neuropathic Pain - Pipeline by Vernalis plc, H1 2014 92
Neuropathic Pain - Pipeline by Evotec AG, H1 2014 93
Neuropathic Pain - Pipeline by GW Pharmaceuticals plc, H1 2014 94
Neuropathic Pain - Pipeline by Anavex Life Sciences Corp., H1 2014 95
Neuropathic Pain - Pipeline by IntelGenx Corp., H1 2014 96
Neuropathic Pain - Pipeline by Lpath, Inc., H1 2014 97
Neuropathic Pain - Pipeline by Medivir AB, H1 2014 98
Neuropathic Pain - Pipeline by Benitec Biopharma Limited, H1 2014 99
Neuropathic Pain - Pipeline by Bionomics Limited, H1 2014 100
Neuropathic Pain - Pipeline by Nuvo Research Inc., H1 2014 101
Neuropathic Pain - Pipeline by Zalicus Inc., H1 2014 102
Neuropathic Pain - Pipeline by Nippon Chemiphar Co., Ltd., H1 2014 103
Neuropathic Pain - Pipeline by Torrent Pharmaceuticals Limited, H1 2014 104
Neuropathic Pain - Pipeline by KunWha Pharmaceutical Co., Ltd., H1 2014 105
Neuropathic Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2014 106
Neuropathic Pain - Pipeline by Pluristem Therapeutics Inc., H1 2014 107
Neuropathic Pain - Pipeline by Suven Life Sciences Ltd., H1 2014 108
Neuropathic Pain - Pipeline by Newron Pharmaceuticals S.p.A., H1 2014 109
Neuropathic Pain - Pipeline by Debiopharm International S.A., H1 2014 110
Neuropathic Pain - Pipeline by Auspex Pharmaceuticals, Inc., H1 2014 111
Neuropathic Pain - Pipeline by Colby Pharmaceutical Company, H1 2014 112
Neuropathic Pain - Pipeline by VistaGen Therapeutics , Inc., H1 2014 113
Neuropathic Pain - Pipeline by Palau Pharma, S.A., H1 2014 114
Neuropathic Pain - Pipeline by Snowdon Inc., H1 2014 115
Neuropathic Pain - Pipeline by Pharmaleads, H1 2014 116
Neuropathic Pain - Pipeline by Neurotune AG, H1 2014 117
Neuropathic Pain - Pipeline by Grunenthal GmbH, H1 2014 118
Neuropathic Pain - Pipeline by Amura Holdings Ltd., H1 2014 119
Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H1 2014 120
Neuropathic Pain - Pipeline by AngioChem Inc., H1 2014 121
Neuropathic Pain - Pipeline by PharmEste, H1 2014 122
Neuropathic Pain - Pipeline by Trevena, Inc., H1 2014 123
Neuropathic Pain - Pipeline by Asahi Kasei Pharma Corp., H1 2014 124
Neuropathic Pain - Pipeline by Syntrix Biosystems, Inc., H1 2014 125
Neuropathic Pain - Pipeline by GP Pharm, S.A., H1 2014 126
Neuropathic Pain - Pipeline by Kineta, Inc., H1 2014 127
Neuropathic Pain - Pipeline by WEX Pharmaceuticals Inc., H1 2014 128
Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H1 2014 129
Neuropathic Pain - Pipeline by NeurAxon, Inc., H1 2014 130
Neuropathic Pain - Pipeline by Virobay Inc., H1 2014 131
Neuropathic Pain - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 132
Neuropathic Pain - Pipeline by Knopp Biosciences LLC, H1 2014 133
Neuropathic Pain - Pipeline by QRxPharma Limited, H1 2014 134
Neuropathic Pain - Pipeline by Cara Therapeutics, Inc., H1 2014 135
Neuropathic Pain - Pipeline by Targacept, Inc., H1 2014 136
Neuropathic Pain - Pipeline by Intellipharmaceutics International Inc., H1 2014 137
Neuropathic Pain - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2014 138
Neuropathic Pain - Pipeline by to-BBB technologies BV, H1 2014 139
Neuropathic Pain - Pipeline by Lipopharma Therapeutics SL, H1 2014 140
Neuropathic Pain - Pipeline by Winston Pharmaceuticals, Inc., H1 2014 141
Neuropathic Pain - Pipeline by Medisyn Technologies, Inc., H1 2014 142
Neuropathic Pain - Pipeline by Maruho Co., Ltd., H1 2014 143
Neuropathic Pain - Pipeline by Bial - Portela & Ca, S.A., H1 2014 144
Neuropathic Pain - Pipeline by CLL Pharma, H1 2014 145
Neuropathic Pain - Pipeline by Beijing Tide Pharmaceutical Co., Ltd., H1 2014 146
Neuropathic Pain - Pipeline by Spinifex Pharmaceuticals Pty Limited, H1 2014 147
Neuropathic Pain - Pipeline by Trigemina, Inc., H1 2014 148
Neuropathic Pain - Pipeline by MediProPharma, Inc., H1 2014 149
Neuropathic Pain - Pipeline by Vichem Chemie Research Ltd., H1 2014 150
Neuropathic Pain - Pipeline by RaQualia Pharma Inc., H1 2014 151
Neuropathic Pain - Pipeline by Naurex, Inc., H1 2014 152
Neuropathic Pain - Pipeline by Relevare Pharmaceuticals Ltd., H1 2014 153
Neuropathic Pain - Pipeline by NeurOp Corporation, H1 2014 154
Neuropathic Pain - Pipeline by Nectid, Inc., H1 2014 155
Neuropathic Pain - Pipeline by Convergence Pharmaceuticals Ltd., H1 2014 156
Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H1 2014 157
Neuropathic Pain - Pipeline by Adynxx, Inc., H1 2014 158
Neuropathic Pain - Pipeline by Cerecor Inc., H1 2014 159
Neuropathic Pain - Pipeline by Recro Pharma, Inc., H1 2014 160
Neuropathic Pain - Pipeline by Theralpha SAS, H1 2014 161
Neuropathic Pain - Pipeline by Creabilis SA, H1 2014 162
Neuropathic Pain - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 163
Neuropathic Pain - Pipeline by RAPID Pharmaceuticals AG, H1 2014 164
Neuropathic Pain - Pipeline by Neurodyn Inc., H1 2014 165
Neuropathic Pain - Pipeline by AbbVie Inc., H1 2014 166
Neuropathic Pain - Pipeline by Aniona ApS, H1 2014 167
Neuropathic Pain - Pipeline by Ziarco Pharma Ltd, H1 2014 168
Neuropathic Pain - Pipeline by Glialogix, Inc., H1 2014 169
Assessment by Monotherapy Products, H1 2014 170
Number of Products by Stage and Target, H1 2014 173
Number of Products by Stage and Mechanism of Action, H1 2014 180
Number of Products by Stage and Route of Administration, H1 2014 187
Number of Products by Stage and Molecule Type, H1 2014 190
Neuropathic Pain Therapeutics - Recent Pipeline Updates, H1 2014 432
Neuropathic Pain - Dormant Projects, H1 2014 476
Neuropathic Pain - Discontinued Products, H1 2014 478
List of Figures
Number of Products under Development for Neuropathic Pain, H1 2014 31
Number of Products under Development for Neuropathic Pain - Comparative Analysis, H1 2014 32
Number of Products under Development by Companies, H1 2014 33
Number of Products under Investigation by Universities/Institutes, H1 2014 42
Comparative Analysis by Late Stage Development, H1 2014 45
Comparative Analysis by Clinical Stage Development, H1 2014 46
Comparative Analysis by Early Stage Products, H1 2014 47
Assessment by Monotherapy Products, H1 2014 170
Number of Products by Top 10 Target, H1 2014 171
Number of Products by Stage and Top 10 Target, H1 2014 172
Number of Products by Top 10 Mechanism of Action, H1 2014 178
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 179
Number of Products by Top 10 Route of Administration, H1 2014 185
Number of Products by Stage and Top 10 Route of Administration, H1 2014 186
Number of Products by Top 10 Molecule Type, H1 2014 188
Number of Products by Stage and Top 10 Molecule Type, H1 2014 189
Table of Contents 2
Introduction 7
Neuropathic Pain Overview 8
Therapeutics Development 9
Neuropathic Pain - Therapeutics under Development by Companies 11
Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 20
Neuropathic Pain - Pipeline Products Glance 23
Neuropathic Pain - Products under Development by Companies 27
Neuropathic Pain - Products under Investigation by Universities/Institutes 38
Neuropathic Pain - Companies Involved in Therapeutics Development 40
Neuropathic Pain - Therapeutics Assessment 148
Drug Profiles 169
Neuropathic Pain - Recent Pipeline Updates 410
Neuropathic Pain - Dormant Projects 454
Neuropathic Pain - Discontinued Products 456
Neuropathic Pain - Product Development Milestones 457
Appendix 463
List of Tables
Number of Products under Development for Neuropathic Pain, H1 2014 31
Number of Products under Development for Neuropathic Pain - Comparative Analysis, H1 2014 32
Number of Products under Development by Companies, H1 2014 34
Number of Products under Development by Companies, H1 2014 (Contd..1) 35
Number of Products under Development by Companies, H1 2014 (Contd..2) 36
Number of Products under Development by Companies, H1 2014 (Contd..3) 37
Number of Products under Development by Companies, H1 2014 (Contd..4) 38
Number of Products under Development by Companies, H1 2014 (Contd..5) 39
Number of Products under Development by Companies, H1 2014 (Contd..6) 40
Number of Products under Development by Companies, H1 2014 (Contd..7) 41
Number of Products under Investigation by Universities/Institutes, H1 2014 43
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 44
Comparative Analysis by Late Stage Development, H1 2014 45
Comparative Analysis by Clinical Stage Development, H1 2014 46
Comparative Analysis by Early Stage Development, H1 2014 47
Comparative Analysis by Unknown Stage Development, H1 2014 48
Products under Development by Companies, H1 2014 49
Products under Development by Companies, H1 2014 (Contd..1) 50
Products under Development by Companies, H1 2014 (Contd..2) 51
Products under Development by Companies, H1 2014 (Contd..3) 52
Products under Development by Companies, H1 2014 (Contd..4) 53
Products under Development by Companies, H1 2014 (Contd..5) 54
Products under Development by Companies, H1 2014 (Contd..6) 55
Products under Development by Companies, H1 2014 (Contd..7) 56
Products under Development by Companies, H1 2014 (Contd..8) 57
Products under Development by Companies, H1 2014 (Contd..9) 58
Products under Development by Companies, H1 2014 (Contd..10) 59
Products under Investigation by Universities/Institutes, H1 2014 60
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 61
Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H1 2014 62
Neuropathic Pain - Pipeline by Genzyme Corporation, H1 2014 63
Neuropathic Pain - Pipeline by Johnson & Johnson, H1 2014 64
Neuropathic Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2014 65
Neuropathic Pain - Pipeline by Biogen Idec Inc., H1 2014 66
Neuropathic Pain - Pipeline by Shionogi & Co., Ltd., H1 2014 67
Neuropathic Pain - Pipeline by AstraZeneca PLC, H1 2014 68
Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2014 69
Neuropathic Pain - Pipeline by Nektar Therapeutics, H1 2014 70
Neuropathic Pain - Pipeline by MedImmune, LLC, H1 2014 71
Neuropathic Pain - Pipeline by Quark Pharmaceuticals, Inc., H1 2014 72
Neuropathic Pain - Pipeline by Merck & Co., Inc., H1 2014 73
Neuropathic Pain - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 74
Neuropathic Pain - Pipeline by Sangamo BioSciences, Inc., H1 2014 75
Neuropathic Pain - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 76
Neuropathic Pain - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 77
Neuropathic Pain - Pipeline by XenoPort, Inc., H1 2014 78
Neuropathic Pain - Pipeline by BioLineRx, Ltd., H1 2014 79
Neuropathic Pain - Pipeline by Neurocrine Biosciences, Inc., H1 2014 80
Neuropathic Pain - Pipeline by Acorda Therapeutics, Inc., H1 2014 81
Neuropathic Pain - Pipeline by Astellas Pharma Inc., H1 2014 82
Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 83
Neuropathic Pain - Pipeline by Eisai Co., Ltd., H1 2014 84
Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2014 85
Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2014 86
Neuropathic Pain - Pipeline by LEO Pharma A/S, H1 2014 87
Neuropathic Pain - Pipeline by Pfizer Inc., H1 2014 88
Neuropathic Pain - Pipeline by Sigma-Tau S.p.A., H1 2014 89
Neuropathic Pain - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 90
Neuropathic Pain - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 91
Neuropathic Pain - Pipeline by Vernalis plc, H1 2014 92
Neuropathic Pain - Pipeline by Evotec AG, H1 2014 93
Neuropathic Pain - Pipeline by GW Pharmaceuticals plc, H1 2014 94
Neuropathic Pain - Pipeline by Anavex Life Sciences Corp., H1 2014 95
Neuropathic Pain - Pipeline by IntelGenx Corp., H1 2014 96
Neuropathic Pain - Pipeline by Lpath, Inc., H1 2014 97
Neuropathic Pain - Pipeline by Medivir AB, H1 2014 98
Neuropathic Pain - Pipeline by Benitec Biopharma Limited, H1 2014 99
Neuropathic Pain - Pipeline by Bionomics Limited, H1 2014 100
Neuropathic Pain - Pipeline by Nuvo Research Inc., H1 2014 101
Neuropathic Pain - Pipeline by Zalicus Inc., H1 2014 102
Neuropathic Pain - Pipeline by Nippon Chemiphar Co., Ltd., H1 2014 103
Neuropathic Pain - Pipeline by Torrent Pharmaceuticals Limited, H1 2014 104
Neuropathic Pain - Pipeline by KunWha Pharmaceutical Co., Ltd., H1 2014 105
Neuropathic Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2014 106
Neuropathic Pain - Pipeline by Pluristem Therapeutics Inc., H1 2014 107
Neuropathic Pain - Pipeline by Suven Life Sciences Ltd., H1 2014 108
Neuropathic Pain - Pipeline by Newron Pharmaceuticals S.p.A., H1 2014 109
Neuropathic Pain - Pipeline by Debiopharm International S.A., H1 2014 110
Neuropathic Pain - Pipeline by Auspex Pharmaceuticals, Inc., H1 2014 111
Neuropathic Pain - Pipeline by Colby Pharmaceutical Company, H1 2014 112
Neuropathic Pain - Pipeline by VistaGen Therapeutics , Inc., H1 2014 113
Neuropathic Pain - Pipeline by Palau Pharma, S.A., H1 2014 114
Neuropathic Pain - Pipeline by Snowdon Inc., H1 2014 115
Neuropathic Pain - Pipeline by Pharmaleads, H1 2014 116
Neuropathic Pain - Pipeline by Neurotune AG, H1 2014 117
Neuropathic Pain - Pipeline by Grunenthal GmbH, H1 2014 118
Neuropathic Pain - Pipeline by Amura Holdings Ltd., H1 2014 119
Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H1 2014 120
Neuropathic Pain - Pipeline by AngioChem Inc., H1 2014 121
Neuropathic Pain - Pipeline by PharmEste, H1 2014 122
Neuropathic Pain - Pipeline by Trevena, Inc., H1 2014 123
Neuropathic Pain - Pipeline by Asahi Kasei Pharma Corp., H1 2014 124
Neuropathic Pain - Pipeline by Syntrix Biosystems, Inc., H1 2014 125
Neuropathic Pain - Pipeline by GP Pharm, S.A., H1 2014 126
Neuropathic Pain - Pipeline by Kineta, Inc., H1 2014 127
Neuropathic Pain - Pipeline by WEX Pharmaceuticals Inc., H1 2014 128
Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H1 2014 129
Neuropathic Pain - Pipeline by NeurAxon, Inc., H1 2014 130
Neuropathic Pain - Pipeline by Virobay Inc., H1 2014 131
Neuropathic Pain - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 132
Neuropathic Pain - Pipeline by Knopp Biosciences LLC, H1 2014 133
Neuropathic Pain - Pipeline by QRxPharma Limited, H1 2014 134
Neuropathic Pain - Pipeline by Cara Therapeutics, Inc., H1 2014 135
Neuropathic Pain - Pipeline by Targacept, Inc., H1 2014 136
Neuropathic Pain - Pipeline by Intellipharmaceutics International Inc., H1 2014 137
Neuropathic Pain - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2014 138
Neuropathic Pain - Pipeline by to-BBB technologies BV, H1 2014 139
Neuropathic Pain - Pipeline by Lipopharma Therapeutics SL, H1 2014 140
Neuropathic Pain - Pipeline by Winston Pharmaceuticals, Inc., H1 2014 141
Neuropathic Pain - Pipeline by Medisyn Technologies, Inc., H1 2014 142
Neuropathic Pain - Pipeline by Maruho Co., Ltd., H1 2014 143
Neuropathic Pain - Pipeline by Bial - Portela & Ca, S.A., H1 2014 144
Neuropathic Pain - Pipeline by CLL Pharma, H1 2014 145
Neuropathic Pain - Pipeline by Beijing Tide Pharmaceutical Co., Ltd., H1 2014 146
Neuropathic Pain - Pipeline by Spinifex Pharmaceuticals Pty Limited, H1 2014 147
Neuropathic Pain - Pipeline by Trigemina, Inc., H1 2014 148
Neuropathic Pain - Pipeline by MediProPharma, Inc., H1 2014 149
Neuropathic Pain - Pipeline by Vichem Chemie Research Ltd., H1 2014 150
Neuropathic Pain - Pipeline by RaQualia Pharma Inc., H1 2014 151
Neuropathic Pain - Pipeline by Naurex, Inc., H1 2014 152
Neuropathic Pain - Pipeline by Relevare Pharmaceuticals Ltd., H1 2014 153
Neuropathic Pain - Pipeline by NeurOp Corporation, H1 2014 154
Neuropathic Pain - Pipeline by Nectid, Inc., H1 2014 155
Neuropathic Pain - Pipeline by Convergence Pharmaceuticals Ltd., H1 2014 156
Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H1 2014 157
Neuropathic Pain - Pipeline by Adynxx, Inc., H1 2014 158
Neuropathic Pain - Pipeline by Cerecor Inc., H1 2014 159
Neuropathic Pain - Pipeline by Recro Pharma, Inc., H1 2014 160
Neuropathic Pain - Pipeline by Theralpha SAS, H1 2014 161
Neuropathic Pain - Pipeline by Creabilis SA, H1 2014 162
Neuropathic Pain - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 163
Neuropathic Pain - Pipeline by RAPID Pharmaceuticals AG, H1 2014 164
Neuropathic Pain - Pipeline by Neurodyn Inc., H1 2014 165
Neuropathic Pain - Pipeline by AbbVie Inc., H1 2014 166
Neuropathic Pain - Pipeline by Aniona ApS, H1 2014 167
Neuropathic Pain - Pipeline by Ziarco Pharma Ltd, H1 2014 168
Neuropathic Pain - Pipeline by Glialogix, Inc., H1 2014 169
Assessment by Monotherapy Products, H1 2014 170
Number of Products by Stage and Target, H1 2014 173
Number of Products by Stage and Mechanism of Action, H1 2014 180
Number of Products by Stage and Route of Administration, H1 2014 187
Number of Products by Stage and Molecule Type, H1 2014 190
Neuropathic Pain Therapeutics - Recent Pipeline Updates, H1 2014 432
Neuropathic Pain - Dormant Projects, H1 2014 476
Neuropathic Pain - Discontinued Products, H1 2014 478
List of Figures
Number of Products under Development for Neuropathic Pain, H1 2014 31
Number of Products under Development for Neuropathic Pain - Comparative Analysis, H1 2014 32
Number of Products under Development by Companies, H1 2014 33
Number of Products under Investigation by Universities/Institutes, H1 2014 42
Comparative Analysis by Late Stage Development, H1 2014 45
Comparative Analysis by Clinical Stage Development, H1 2014 46
Comparative Analysis by Early Stage Products, H1 2014 47
Assessment by Monotherapy Products, H1 2014 170
Number of Products by Top 10 Target, H1 2014 171
Number of Products by Stage and Top 10 Target, H1 2014 172
Number of Products by Top 10 Mechanism of Action, H1 2014 178
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 179
Number of Products by Top 10 Route of Administration, H1 2014 185
Number of Products by Stage and Top 10 Route of Administration, H1 2014 186
Number of Products by Top 10 Molecule Type, H1 2014 188
Number of Products by Stage and Top 10 Molecule Type, H1 2014 189
